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Blooms of the dinoflagellate Karenia brevis
are responsible for what are commonly
referred to as Florida red tides. K. brevis pro-
duces a series of potent neurotoxins known
as brevetoxins (Baden 1989). The reader is
referred to reviews by Fleming et al. (2005a)
and Kirkpatrick et al. (2004) for discussion
of Florida red tide exposures, effects, and
implications for human health.
K. brevis red tides occur almost annually
in the Gulf of Mexico and have increased in
geographic distribution since the 1970s
(Van Dolah 2000). Therefore, the possibility
of repeated inhalation exposure for individu-
als working and living along affected beaches
and waterways is increasing. Despite this, lit-
tle is known about the possible systemic
health effects associated with aerosolized
brevetoxins beyond the obvious immediate
upper respiratory tract irritation (Backer et al.
2003; Kirkpatrick et al. 2004). Bossart et al.
(1998) reported respiratory tract inflamma-
tion and hemopathy in manatees dying
during extensive 1996 K. brevis red tides.
Immunohistochemical staining of tissues from
these manatees indicated an accumulation of
brevetoxins in tissue macrophages and lym-
phocytes, key players in humoral and cell-
mediated immune responses. Although these
effects in manatees occurred after weeks of
exposure via several routes, the data suggest
that the respiratory tract, hematopoietic, and
immune systems might be targets for
brevetoxin-induced toxicity after repeated
exposure of humans to environmentally rele-
vant airborne concentrations of brevetoxins.
In animal studies with inhaled brevetox-
ins, suppressed splenic antibody production
was observed among Sprague-Dawley rats
inhaling aerosols of crude K. brevis extract
4 hr/day for 1 and 4 weeks. No toxicity to the
nervous, respiratory, or hematopoietic systems
was noted (Benson et al. 2003). The extract
contained primarily brevetoxins 2 and 3 but
also contained brevenal, a newly identified
compound in K. brevis having pharmacologic
activity antagonistic to brevetoxin-induced
neurotoxicity and bronchoconstrictor activi-
ties (Bourdelais et al. 2003; Abraham et al.
2005). Brevetoxin-induced suppression of
splenic antibody production was conﬁrmed in
rats inhaling pure brevetoxin 3 at 500 µg/m3
for 0.5 hr and 2 hr/day for 5 consecutive days
(Benson et al. 2004). Antibody production was
suppressed by > 70% in the low-exposure
(0.5-hr exposure/day) and high-exposure (2-hr
exposure/day) groups. Small numbers of
splenic and peribronchiolar lymphoid tissue
macrophages stained positive for brevetoxin.
No biochemical or histologic evidence of toxi-
city to the respiratory, nervous, or hematopoi-
etic systems was found in the rats inhaling
pure brevetoxin 3 for 5 days.
The purpose of the study reported here
was to extend our investigation of the
adverse systemic health effects associated
with brevetoxin inhalation exposure, exclusive
of acute respiratory tract irritation.
Brevetoxin 3 was chosen for these studies
because it is a major component of the breve-
toxin mixture produced by K. brevis (Baden
1989) and of brevetoxin-containing aerosols
measured along red tide affected beaches
(Cheng et al. 2005). The exposure scenario
was chosen to more closely mimic a 5 day/
week occupational exposure than occasional
recreational exposure, although daily expo-
sure durations were much shorter (2 hr) than
those expected for occupational exposures.
The aerosol concentrations employed were
2–3 orders of magnitude higher than total
brevetoxin concentrations measured to date
along Florida beaches during red tides of mild
to moderate intensity (Backer et al. 2003;
Cheng et al. 2005; Pierce et al. 2003).
Materials and Methods
Chemicals
Brevetoxin 3 was isolated and purified from
the Wilson clone of K. brevis at the Center for
Marine Sciences, University of North
Carolina, Wilmington. Unless otherwise
specified, all other chemicals, including
3H-thymidine-5 (20–30 Ci/mmol; 95%
radiochemically pure), were purchased from
Sigma Chemical Company (St. Louis, MO).
Animals
Male F344/CrlBr rats, 6–7 weeks old when
received from Charles River Laboratories
(Wilmington, MA), were used. The rats were
housed in polycarbonate cages with hard-
wood chip bedding. The animal rooms were
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Brevetoxins are potent neurotoxins produced by the marine dinoflagellate Karenia brevis.
Exposure to brevetoxins may occur during a K. brevis red tide when the compounds become
aerosolized by wind and surf. This study assessed possible adverse health effects associated with
inhalation exposure to brevetoxin 3, one of the major brevetoxins produced by K. brevis and pre-
sent in aerosols collected along beaches affected by red tide. Male F344 rats were exposed to breve-
toxin 3 at 0, 37, and 237 µg/m3 by nose-only inhalation 2 hr/day, 5 days/week for up to
22 exposure days. Estimated deposited brevetoxin 3 doses were 0.9 and 5.8 µg/kg/day for the low-
and high-dose groups, respectively. Body weights of the high-dose group were signiﬁcantly below
control values. There were no clinical signs of toxicity. Terminal body weights of both low- and
high-dose-group rats were signiﬁcantly below control values. Minimal alveolar macrophage hyper-
plasia was observed in three of six and six of six of the low- and high-dose groups, respectively. No
histopathologic lesions were observed in the nose, brain, liver, or bone marrow of any group.
Reticulocyte numbers in whole blood were significantly increased in the high-dose group, and
mean corpuscular volume showed a signiﬁcant decreasing trend with increasing exposure concen-
tration. Humoral-mediated immunity was suppressed in brevetoxin-exposed rats as indicated by
signiﬁcant reduction in splenic plaque-forming cells in both low- and high-dose-group rats com-
pared with controls. Results indicate that the immune system is the primary target for toxicity in
rats after repeated inhalation exposure to relatively high concentrations of brevetoxins. Key words:
brevetoxin, immunotoxicity, inhalation, neurotoxicity, rats. Environ Health Perspect 113:626–631
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ity at 20–50% and a 12-hr light cycle begin-
ning at 0600 hr. Food [Harlan Teklad rodent
diet (W), Madison, WI] and water were pro-
vided ad libitum. The rats were randomized
by weight into exposure groups and weighed
230.3 ± 8.3 g (mean ± SD; n = 66) when
exposures began. The rats were conditioned
to the nose-only inhalation restraint tubes for
0.5, 1, and 2 hr before initiation of exposures.
The study protocol was reviewed and
approved by the Lovelace Respiratory
Research Institute Institutional Animal Care
and Use Committee.
Exposure System
The exposure system consisted of three,
36-port cylindrical nose-only inhalation cham-
bers (InTox Products, Edgewood, NM), each
supplied with a single nebulizer (Hospitak,
Inc., Farmingdale, NY). Aerosols generated in
the nebulizer were dried and diluted with sup-
ply air to achieve the desired chamber aerosol
concentrations. Flow rate through the cham-
ber was 10 L/min. Temperatures were moni-
tored continuously with an acceptable range of
18–22°C. Chamber oxygen concentration was
monitored continuously with an action level
at ≤ 18%.
Aerosol Generation and
Characterization
The aerosols used in this study were saline
based, to mimic sodium chloride–based
marine aerosols. Stock solutions containing
0.5 mg brevetoxin/mLwere prepared in 100%
ethanol. Generator solutions for the nebulizers
supplying the low- and high-level exposure
chambers were prepared daily by diluting the
stock solutions with 0.9% saline to achieve a
ﬁnal concentration of 0.15 mg/mL. The gen-
erator solution for the control chamber was
ethanol–saline. Target total exposure concen-
trations were 5 mg total aerosol/m3 for the
low-level exposure chamber and 20 mg total
aerosol/m3 for the control and high-level
exposure chambers. Target exposure concen-
trations were achieved by operating the nebu-
lizer at 2 psi for the low-level exposure
chamber and 4 psi for the control and high-
level exposure chambers. The total aerosol
concentrations of the saline-based aerosols in
the exposure atmospheres were determined
gravimetrically. Aerosol was collected from the
breathing zone of the animals at a ﬂow rate of
2 L/min onto preweighed 25-mm Zeﬂuor ﬁl-
ters (SKC Gulf Coast, Houston, TX) at 0.5-hr
intervals. The stability of the total aerosol con-
centration during the exposure was monitored
using a TSI DustTrak real-time aerosol moni-
tor (TSI Industries, Shoreview, MN). The
particle size distributions [mass median aero-
dynamic diameter (MMAD) and geometric
standard deviation (σg)] of the aerosols were
determined using an eight-stage cascade
impactor (InTox Products).
To directly quantitate brevetoxin concen-
tration in the exposure atmosphere, selected
filter samples were extracted with acetone
(Fisher Scientific, Fairlawn, NJ), dried, and
resuspended in methanol and water (50:50).
Extracts were spiked with brevetoxin 2 as an
internal standard. Samples were injected onto
a high-pressure liquid chromatograph
(10ADVP; Shimadzu Company, Kyoto,
Japan) equipped with a 75 × 2-mm analytical
column (Aqua 3 µm, Phenomenex USA,
Torrance, CA). Brevetoxin was eluted using a
methanol–water mobile phase containing
1 mM ammonium acetate. Eluant was directed
into an electrospray mass spectrometer (API
365; Applied Biosystems, Foster City, CA).
The mass spectrometer was monitored for ion
pairs consisting of 897.590/725.404 (breve-
toxin 3) and 895.559/877.550 (brevetoxin 2).
Aerosol concentrations were confirmed by
enzyme-linked immunosorbent assay (ELISA)
analysis (Naar et al. 2002) performed on the
above ﬁlter extracts.
To determine the concentration of
ethanol vapor in the exposure atmosphere, a
sample of the control chamber exposure
atmosphere was collected into a Tedlar bag
obtained using an SKC Vac-U Chamber
(SKC Inc., Eighty Four, PA). A glass-fiber
filter was placed in line to remove particles
from the sample before it entered the sam-
pling bag. The ethanol concentration in the
sample was measured by gas chromatography
with flame ionization using a Shimadzu
Model GC-17A/FID (Shimadzu Scientific
Instruments, Columbia, MD) equipped with
a Restek Rtx-1 column (30-m × 0.32-mm ×
5-µm film width; Restek Corporation,
Bellefonte, PA). The chromatograph oven
was operated isothermally at 50°C. The injec-
tor and detector temperatures were 200°C. A
five-point ethanol vapor standard curve was
over a concentration range of 1.16–9.4 g/m3
was used.
Experimental Design
Subgroup A rats (n = 6 per exposure level)
were exposed 2 hr/day, 5 days/week for a total
of 22 exposure days. End points specific to
this group included gross and histopathology,
hematology, serum chemistry, and evaluations
of bronchoalveolar lavage ﬂuid for indications
of cytotoxicity [lactate dehydrogenase (LDH)
activity] and inﬂammation (total protein, total
and differential nucleated cell counts), and
splenocyte proliferation in response to mito-
gen in vitro. Subgroup B rats (n = 10 per
exposure level) were sacrificed after 5 and
22 days of exposure (n = 5 per sacriﬁce time)
for quantitation of brevetoxin 3 or metabolites
in liver, the organ expected to have the great-
est dose (Benson et al. 1999; Cattet and
Geraci 1993; Poli et al. 1990), and for evalua-
tion of splenocyte antigen recognition in vitro
after 22 days of exposure.
In Vivo Observations
All rats were observed for clinical signs of
toxicity, especially neurotoxicity, after each
day’s exposure. In addition, the rats were
weighed, and detailed clinical observations
were recorded weekly (Path Tox Software;
Xybion, Cedar Knolls, NJ).
Necropsy
All rats were sacriﬁced by intraperitoneal injec-
tion of an overdose of Euthasol (Virbac AH
Inc., Fort Worth, TX). Body weights were
recorded for all rats at the 4-week (terminal)
sacriﬁce. Blood was collected from subgroup A
rats by cardiac puncture for evaluation of
hematology and serum chemistry. Each sub-
group A rat (n = 6) received a complete
necropsy. Brain, lung, liver, kidney, and
spleen weights were recorded. To obtain bron-
choalveolar lavage ﬂuid, the left lung bronchus
was clamped, and the right lobes were lavaged
twice with 4 mL physiologic saline. After the
lavage, the right bronchus was clamped, and
the left bronchus was unclamped. The left
lobe was ﬁxed via the trachea using 10% neu-
tral-buffered formalin. The nose, brain, liver,
kidney, femur with marrow, and spleen (half)
were also fixed in 10% neutral-buffered for-
malin for histologic evaluation. Splenocytes
were isolated from the remaining half of
spleen for evaluation of their proliferative
response to mitogen challenge in vitro.
Histopathology
The soft tissues were trimmed and embedded
in paraffin. Tissues were sectioned at 5 µm
and stained with hematoxylin and eosin. To
more closely examine brain tissue for neu-
ronal damage, three cross sections of brain
(level of optic chiasma, caudal to mammillary
bodies and caudal to transverse fibers of the
pons) were stained with luxol fast blue-cresyl
violet. These cross-sections contain proﬁles of
the cerebellar cortex, hippocampus, and thala-
mus. The focus was on the neurons in these
regions because of indications of neuronal
damage and loss in these regions in mice
inhaling brevetoxin 3 (Murray TF, unpub-
lished results) and because of the defined
nature of these groups of neurons.
Clinical Pathology
Hematologic evaluations on whole blood
obtained at necropsy were performed using an
Advia 120 Hematology System (Bayer,
Terrytown, NJ). Clinical chemistry evaluations
on serum were performed using a Hitachi 911
Automatic Analyzer (Roche Diagnostic Corp.,
Indianapolis, IN). Standards and reagents
were purchased from Pointe Scientific
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Ltd., Oxford, CT).
Lavage Fluid Analysis
The volume of fluid recovered in the first
lavage wash was recorded. Nucleated cells
were sedimented by centrifugation. The
supernatant from the ﬁrst lavage was analyzed
for LDH and total protein using the
Hitachi 911 Automatic Analyzer. The cell
pellets from both washes from each animal
were pooled and counted manually using a
hemocytometer. Differential counts of nucle-
ated cells were made on cytocentrifuge prepa-
rations stained with Kwik Diff (Shandon,
Inc., Pittsburgh, PA).
The state of activation of the macrophages
recovered in lavage ﬂuid was determined using
a zymosan-stimulated chemiluminescence
assay (Benson et al. 2004; Hubbs et al. 2001).
The assay was conducted on 2 × 105 alveolar
macrophages per sample well in a total vol-
ume of 0.15 mL 1-piperazine ethane sulfonic
acid, 4-(2-hydroxyethyl)-monosodium salt
(HEPES) buffer.
Brevetoxin Concentration in Liver
Rats were sacriﬁced by intraperitoneal injection
of Euthasol approximately 24 hr after expo-
sure. The liver was removed, weighed, and
frozen (–20°C) pending analysis. Thawed tis-
sues were homogenized and 1-g aliquots of tis-
sue homogenate were extracted three times
with 4 mL acetone. The acetone extracts for
each sample were analyzed for brevetoxin 3 or
metabolites by ELISA as described by Naar
et al. (2002).
Immune Responses
Antibody-forming cell response. The immuno-
globin M (IgM) antibody-forming cell response
to the T-cell–dependent antigen sheep red
blood cells (SRBCs) was assessed with a modi-
fied plaque-forming assay (Cunningham
and Szenberg 1968). Subgroup B rats were
immunized by tail vein injection (250 µL of a
15% suspension of SRBC in phosphate
buffered saline). At 7 days postimmunization
the rats were euthanized by intraperitoneal
injection of an overdose of Euthasol. Cells
were isolated from weighed portions of spleen,
washed, and then resuspended in complete
RPMI culture medium to a final concentra-
tion of 1 × 106 cells/mL. Analyses were
performed as described previously (Benson
et al. 2004).
Spleen lymphocyte proliferation. The
proliferative response of the spleen cells to the
mitogen, concanavalin A (Con A) was
assessed. Group A spleen cells (5 × 105/100 L
complete RPMI medium) were incubated
with 0.1, 0.3, and 1.0 µg Con A/50 µL,
respectively, at 37°C in the presence of 5%
CO2 for 54 hr. At that time, cells were pulsed
with 0.5 µCi 3H-thymidine and incubated for
an additional 18 hr. Cells were collected on
filter paper using a cell harvester, and
3H activity (decays per minute) was deter-
mined by liquid scintillation spectrometry.
Statistical Analyses
Means, standard deviations, and standard
errors for experimental parameters other
than body and organ weights were calculated
using Microsoft Excel software (Microsoft
Corporation, Redmond, WA). One-way
analysis of variance (ANOVA) was used to test
if there was a statistically signiﬁcant trend in
the data (GraphPad Software, Inc., San Diego,
CA). If group variances were not signiﬁcantly
different, the ANOVAs were performed with
a Dunnett’s post-test to assess differences
between the control and brevetoxin-exposure
groups. If group variances were significantly
different, the Kruskal-Wallis test was used
coupled with Dunn’s post-test for compar-
isons of exposed versus the control groups.
Group mean body weight and organ weight
data were tested for statistical signiﬁcance using
Path-Tox software. Bartlett’s test was used to
establish the homogeneity of the data. If the
data were homogeneous, signiﬁcance was eval-
uated using a modiﬁed Dunnett’s test. If data
were nonhomogeneous, a modiﬁed t-test was
used. For all parameters, the criterion for
signiﬁcance was p < 0.05.
Results
Exposure atmosphere and estimated breve-
toxin 3 respiratory tract deposition. The
characteristics of the exposure atmospheres are
summarized in Table 1. Mean total aerosol
concentrations for the control chamber, the
low-brevetoxin chamber, and high-brevetoxin
chamber were 21.6, 5, and 22.6 mg/m3,
respectively. Mean brevetoxin 3 concentra-
tions, determined by liquid chromatography–
mass spectrometry (LC-MS) analysis of aerosol
filter extracts for the low- and high-level
groups, were 37 and 237 µg/m3, respectively.
Brevetoxin concentrations obtained and by
ELISA were similar to the values obtained by
LC-MS. The particle size distribution indi-
cated that the aerosol was highly respirable in
rats. Assuming a minute volume of 0.25 L/min
and total respiratory tract deposition of approx-
imately 0.2 (for 1 µm particles; Schlesinger
1989), total respiratory tract deposition of
brevetoxin 3 in a 2-hr period would be 0.22
and 1.4 µg/day (0.91 and 5.8 µg/kg/day) for
the low- and high-exposure groups, respec-
tively. The concentration of ethanol vapor in
the control chamber exposure atmosphere was
5.9 g/m3. Because control rats displayed no
clinical signs of toxicity and no biochemical or
histologic change, this ethanol vapor concen-
tration does not appear to be toxic under the
conditions of this experiment.
Body weight gain and clinical signs of
toxicity. Mean group body weights of rats
inhaling the high brevetoxin 3 concentration
were signiﬁcantly below control values 1 week
after initiation of exposure with the effect per-
sisting throughout the exposure period
(Figure 1). No clinical signs of toxicity were
observed at any time.
Terminal body and organ weights.
Terminal body weights were (mean ± SD,
n = 6) 251 ± 9.20, 236 ± 9.49, and 227 ±
7.38 for the control, low-, and high-breve-
toxin groups, respectively. The terminal
body weights for the low- and high-expo-
sure groups were significantly below the
control values. Absolute liver weights for
low- and high-exposure groups and absolute
kidney weight for the high-exposure group
were also significantly lower than their
respective control values (data not shown).
Percent organ to body weight data for liver
and kidney indicate that the depression in
liver and kidney weights was secondary to
overall brevetoxin 3–induced body weight
depression.
Histopathology. The only lesion observed
in the brevetoxin-exposed rats was alveolar
macrophage hyperplasia of minimal severity.
The incidences among the control, low-, and
high-exposure subgroup A rats were 0 of 6,
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Table 1. Exposure atmosphere characteristics.
Brevetoxin 3 Particle size
Exposure Total aerosol (µg/m3 by mass Brevetoxin distribution 
group (mg/m3a) spectrometryb) (µg/m3 by ELISAc) [µm MMAD (σg)]
Vehicle control 21.6 ± 4.72 NAe NA 0.92 (2.12)
Low brevetoxin 3 5.06 ± 0.50 37.4 ± 10 44 ± 22 1.33 (2.05)
High brevetoxin 3 22.6 ± 1.45 237 ± 87 216 ± 56 1.12 (2.37)
NA, not applicable. 
aMean ± SD; n = 23. bMean ± SD; n = 10. cMean ± SD; n = 6–8. 
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Figure 1. Effect of brevetoxin inhalation on body
weight. Values are the mean of ≥ 14 values. 
*Statistically different from control, ANOVA p < 0.05.3 of 6, and 6 of 6, respectively. The hyperplasia
was characterized by a slight increase in the
number of alveolar macrophages in the lung
and occasional alveoli, where two to four were
congregated (Figure 2). Macrophages were also
found in the lumens of terminal bronchioles,
an atypical location for these cells. The cyto-
plasm of the macrophages appeared normal
and was not vacuolated, enlarged, or pig-
mented. No evidence of neuronal damage or
loss was detected in sections of the hippocam-
pus and cerebellar cortex. Occasional neurons
or groups of neurons were crenated and darkly
stained. However, there were no tissue changes
associated with these cells such as edema,
inﬂammatory cell inﬁltrates, macrophages, or
staining alterations of the neutrophil indicat-
ing degeneration of nerve fibers. Therefore,
these darkly stained neurons were interpreted
as ﬁxation artifacts.
Clinical pathology. Brevetoxin inhalation
had no signiﬁcant effect on the total or differ-
ential white blood cell counts (Table 2). The
numbers of reticulocytes were significantly
increased in the high-exposure group, and
there were decreasing trends in mean corpus-
cular volume (p < 0.042) and in the mean
corpuscular hemoglobin concentration
(p < 0.051). However, although there were
slight decreases in the numbers of red blood
cells, hematocrit, and hemoglobin with
increasing exposure levels, these trends were
not statistically signiﬁcant.
High-exposure rats had significant
reductions in serum blood urea nitrogen and
triglyceride concentrations. No significant
trends were observed in any other parameter
examined.
Lavage ﬂuid parameters. The bronchoalve-
olar lavage ﬂuid obtained from the right lungs
of control rats contained (mean ± SD, n =6 )
159 ± 47 mIU of LDH activity, 0.41 ± 0.18
mg of total protein, and 4.67 ± 0.93 million
total nucleated cells. Macrophages comprised
≥ 98% of the nucleated cell population.
Results of the chemilumenescence assays indi-
cated that brevetoxin inhalation did not affect
baseline macrophage activity or the response of
macrophages to particle (zymosan) stimulation
(data not shown).
Brevetoxin concentration in liver. The
limit of detection of brevetoxin in the ELISA
assay is 1 ng/mL for brevetoxin in buffer.
Measured concentrations of brevetoxin and/or
metabolites in low-exposure-group rats were
not signiﬁcantly different from control values
after 5 and 22 days of exposure (Table 3).
Brevetoxin concentrations in liver of high-
exposure-group rats were significantly
increased above background. Brevetoxin con-
centrations in high-exposure-group livers after
5 and 22 days of exposure were not signifi-
cantly different, indicating that no accumula-
tion of brevetoxin or its metabolites in liver
occurs with repeated exposure. The reason for
the relatively high background level in the
control liver 11–12 ng/g liver is not known.
However, because control animals were
exposed in a chamber designated only for con-
trol animals, and all animals were housed indi-
vidually, it is not likely that the background
was due to an inadvertent exposure of the
controls to brevetoxin.
Immune responses. Repeated inhalation
of brevetoxin 3 had no marked effect on
spleen weights or numbers of lymphoid cells
isolated from spleens (Table 4). Numbers of
plaque-forming cells were depressed by
> 60% in spleen cells after inhalation. The
magnitude of suppression did not appear to
be exposure concentration dependent.
However, the high-exposure group’s large
standard deviation makes it difﬁcult to deter-
mine this with certainty.
Lymphocyte proliferation among control
spleen cells stimulated in vitro with 0.1, 0.3,
and 1 µg Con A/well was increased by 54 ± 4-,
45 ± 8-, and 32 ± 3-fold (mean ± SD; n =6 )
over control (unstimulated) lymphocytes,
respectively. Brevetoxin inhalation for 22 days
had no effect on the extent of baseline lym-
phocyte proliferation or response to Con A
(data not shown in Table 4).
Discussion
The purpose of this investigation was to
evaluate the possible toxic effects associated
with repeated inhalation of brevetoxin 3, one
of the major brevetoxins produced by K. bre-
vis. Because the occurrence and distribution
of K. brevis–induced red tide has increased
over time, there may be increased risk from
brevetoxin-induced toxic effects, especially
among individuals working and living along
beaches affected by red tides. Few data are
available on the effects of prolonged exposure
to brevetoxins during red tides.
Rats in this study were exposed to a
highly respirable, sodium chloride–based
aerosol. The aerosol size (0.9–1.3 µm
MMAD) is smaller than that measured along
red tide–affected beaches (~ 6–12.2 µm
MMAD) (Cheng et al. 2005). However,
deposition of both the laboratory-generated
brevetoxin-containing aerosols in rats and the
larger-sized brevetoxin-containing environ-
mental aerosols in humans is expected to
occur primarily in the nasopharyngeal and, to
a lesser extent, in the tracheobronchial and
pulmonary regions (Schlesinger 1989).
Regardless, brevetoxins are highly lipophilic
and are likely absorbed from throughout the
respiratory tract after aerosol deposition. After
absorption, systemic distribution is expected
to occur rapidly, with the liver expected to be
the organ containing a high proportion of the
deposited dose (Benson et al. 1999). We
found signiﬁcant concentrations of brevetoxin
and/or its metabolites in the liver of rats after
5 and 22 days of exposure to only the high
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Figure 2. Increased numbers of alveolar macrophages in the alveoli of a rat exposed to high-brevetoxin
concentration, a typical presentation. (A) Bar = 50 µm. (B) Bar = 25 µm. Arrows indicate macrophages.
Table 2. Effects of brevetoxin inhalation on selected hematology parameters (mean ± SD; n = 6).
WBC RBC Hgb Hct MCV MCH Reticulocytes
Exposure group (× 103 cell/µL) (× 103cells/µL) (g/dL) (%) (fL) (pg) (cells/µL)
Vehicle control 2.75 ± 0.41 8.63 ± 0.34 15.03 ± 0.44 47.18 ± 2.49 54.7 ± 0.88 17.4 ± 1.19 169 ± 13.3
Low brevetoxin 3 3.35 ± 0.76 8.66 ± 0.39 15.12 ± 0.69 46.87 ± 1.76 54.2 ± 0.96 17.5 ± 0.14 194 ± 31.4
High brevetoxin 3 3.27 ± 0.43 8.49 ± 0.19 14.65 ± 0.31 45.47 ± 1.19 53.6 ± 0.69 17.3 ± 0.08 240 ± 13.8*
Abbreviations: Hct, hematocrit; Hgb, hemoglobin; MCH, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RBC, red blood cell count; WBC, white blood cell
count. 
*Mean signiﬁcantly different from control (p ≤ 0.05).brevetoxin concentration (237 µg/m3). The
concentration in liver did not increase with
continued exposure between 5 and 22 days,
suggesting that accumulation in tissue did not
occur with repeated exposure.
We have found no evidence of inﬂamma-
tion in any organ, including the respiratory
tract, in rats inhaling up to 237 µg/m3 for
2 hr/day for up to 22 days, resulting in an esti-
mated deposition of 5.8 µg compound/kg
body weight/day. These results are consistent
with the lack of inflammatory responses in
Sprague-Dawley rats inhaling K. brevis extract
containing 50 or 200 µg brevetoxin/m3 for up
to 4 weeks (Benson et al. 2003) or up to
500 µg/m3 for 5 days (Benson et al. 2004).
The differences in inflammatory responses
between the manatees and rats are likely a
function of differences in overall brevetoxin
exposure; however, there has been no system-
atic investigation on the relative sensitivities of
marine mammals and rats to brevetoxins.
Although minimal macrophage hyperplasia
was noted histologically in the lungs of breve-
toxin 3–exposed rats, significant increases in
macrophage numbers were not found on
examination of bronchoalveolar lavage fluid.
Activation of macrophages was not evident
either morphologically or on examination of
chemiluminescence with or without particle
stimulation. Alveolar macrophage hyperplasia
was not evident in rats inhaling 500 µg/m3
brevetoxin (Benson et al. 2004) for 5 days;
therefore, it appears that prolonged brevetoxin
inhalation may be necessary to induce minimal
changes in macrophage numbers in rat lungs.
We found no evidence for neurotoxicity as
evidenced by clinical signs or upon histopatho-
logic examination of the rats. Lack of neurotox-
icity, especially in the cerebellum, is notable, in
light of the fact that brevetoxin localizes in
rodent cerebellum after a single injection
(Bourdelais et al. 2004) and is cytotoxic in rat
cerebellar granular cells in vitro (Berman and
Murray 1999). However, the relative dose of
brevetoxin to brain is expected to be very low
(< 1% of the initial body burden) compared
with that distributed to carcass (primarily skele-
tal muscle; ~ 48%), gastrointestinal tract
(~ 35%) and liver (~ 10%) based on results
obtained after acute administration via the lung
(Benson et al. 1999). Slow absorption of breve-
toxin that occurs with an inhalation exposure
compared with rapid uptake of a bolus dose
may allow brevetoxin metabolism to less neuro-
toxic metabolites to occur, or allow time for
uptake into tissue sinks such as skeletal muscle.
For example, Poli et al. (1990) have demon-
strated decreased neurotoxicity in rats upon
slow infusion of brevetoxin 3 by injection
compared with administration of a bolus dose.
There was some evidence that brevetoxin
inhalation may affect the hematopoietic sys-
tem. Reticulocyte numbers in blood were
signiﬁcantly increased in the brevetoxin high-
dose group; however, there was no signiﬁcant
effect on erythrocyte count, hemoglobin con-
centration, or hematocrit; and there were no
associated histologic changes in bone marrow.
Decreasing trends in mean corpuscular hemo-
globin volume and corpuscular hemoglobin
concentration were consistent with the
observed increase in reticulocyte counts. The
no-effect level for the increases in reticulocyte
counts in rats was 37 µg of brevetoxin/m3, a
concentration orders of magnitude higher
than the nanogram per cubic meter values
measured to date along Florida beaches dur-
ing red tide events (Cheng et al. 2005).
Although our hematologic findings with
brevetoxin 3 to some extent support the ﬁnd-
ings of hemolytic anemia in manatees exposed
to high brevetoxin concentrations for long
periods (Bossart et al. 1998), the implications
for humans after exposure are limited.
Observed decreases in blood urea nitrogen
and triglyceride levels in serum of high-expo-
sure rats could be associated with reduced
caloric intake, suggested by reduced body
weights in this dose group for most of the
exposure period.
Our findings of suppressed antibody cell
production is consistent with our earlier ﬁnd-
ings in rats inhaling K. brevis extract for
4 weeks as well as pure brevetoxin 3 for 5 days
(Benson et al. 2003, 2004) and reports of
brevetoxin uptake by macrophage and lym-
phocytes in manatees (Bossart et al. 1998).
This ﬁnding is probably the most important
in relation to brevetoxin inhalation because we
have yet to identify a no-effect level in rats.
Therefore, it is possible that some immune
suppression may occur at exposure concentra-
tions encountered in the environment along
red tide affected beaches.
The formation of IgM antibodies in the
plaque-forming assay used requires the interac-
tion of macrophages and B- and T-lympho-
cytes, so the functioning of any or all of these
cells may have been affected by brevetoxin
exposure (Luster et al. 1988). Although breve-
toxins may have affected immune function by
several mechanisms, the absence of histopatho-
logic or changes in spleen weight or splenocyte
numbers, changes in splenocyte profiles, or
responses to mitogens suggest a mechanism
independent of overt cytotoxicity. Cathepsin
inhibition is one likely mechanism underlying
brevetoxin-induced suppression of antibody
production because a) alveolar macrophages,
macrophages within bronchus associated lym-
phoid tissue, and spleen of brevetoxin-exposed
rats stain positively for brevetoxin (Benson
et al. 2003, 2004); b) brevetoxin 2 is a potent
inhibitor of cathepsin L in vitro (Sudarsanam
et al. 1992); and c) cathepsins located within
macrophages and B-lymphocytes play an
important role in the formation of antigenic
determinants essential for both humoral and
cell-mediated immune responses (Katunuma
et al. 2003; Lewis et al. 1998; Riese and
Chapman 2000). One example of an immuno-
toxicant that inhibits primary antibody pro-
duction in vivo by suppressing splenic
cathepsin activity is gallium arsenide (Lewis
et al. 1998). No-effect levels for brevetoxin-
induced suppression of antibody responses,
effects on overall immune competence, and the
role of cathepsin inhibition in these processes
are the foci of future investigations.
Conclusions
Inhalation of 37 and 237 µg/m3 of brevetoxin 3
in a sodium chloride–based aerosol resulted in
some significant reduction in body weight,
minimal alveolar macrophage hyperplasia, and
some alterations in hematologic parameters. No
neurotoxic effects were found. The most signiﬁ-
cant effect of repeated brevetoxin 3 inhalation
was the suppression of antibody production by
splenic lymphocytes. This suppression has been
seen after repeated inhalation of K. brevis
extract for 4 weeks and with inhalation of
brevetoxin 3 for 1 and 4 weeks in rats. These
studies were conducted in young, healthy rats
exposed for short periods of time each day,
although to higher brevetoxin concentrations
than expected to occur in the environment.
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Table 3. Concentrations of brevetoxin 3 or metabolites in rat liver (mean ± SD; n = 3–5).
5-Day sacriﬁce 22-Day sacriﬁce
Exposure group ng/g liver ng/liver ng/g liver ng/liver
Vehicle control 12.1 ± 1.28 106 ± 12.0 11.4 ± 0.44 93.0 ± 5.72
Low brevetoxin 3 16.3 ± 3.39 142 ± 29.8 13.7 ± 1.77 106 ± 18.7
High brevetoxin 3 22.7 ± 7.11* 205 ± 64.9* 29.9 ± 8.60* 215 ± 63.2*
*Mean signiﬁcantly different from control (p ≤ 0.05).
Table 4. Effect of brevetoxin inhalation for 22 days on antibody-forming cell response (mean ± SD; n = 4–5).
Plaque-forming cells 
Exposure group Spleen weight Lymphocytes × 106 per 106 lymphocytes
Vehicle control 0.51 ± 0.04 114 ± 29 560 ± 164
Low brevetoxin 3 0.49 ± 0.02 126 ± 33 155 ± 87*
High brevetoxin 3 0.48 ± 0.03 124 ± 32 235 ± 227*
*Mean signiﬁcantly different from control (p ≤ 0.05).Mini-Monograph | Inhalation toxicity of brevetoxin 3
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Potential adverse health effects on the very
young or aged laboratory animals remain to be
determined. Therefore, much remains to be
learned about the long-term health effects of
repeated inhalation exposure to brevetoxins.
The reader is referred to studies by Fleming
et al. (2005b) and Abraham et al. (2005) for
discussion of the effects of inhaled brevetoxins
on respiratory function in asthmatic humans
and in an animal model of allergy, respectively.
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